IFIH1 and interstitial lung disease: Long‐term use of glucocorticoids can lead to many adverse reactions, a high risk of immunosuppressive infections, unpredictable adverse drug reactions, and the duration of treatment with anti‐pulmonary fibrosis drugs is not easy to manage, resulting in DM‐ILD patients, especially those with positive anti‐MDA5 antibodies.